J. Mgogwe, H. Semvua, Oliva Safari, G. Kapanda, B. Nyombi, J. Chilongola
{"title":"坦桑尼亚结核分枝杆菌耐多药突变的流行和分布","authors":"J. Mgogwe, H. Semvua, Oliva Safari, G. Kapanda, B. Nyombi, J. Chilongola","doi":"10.24248/EASCI.V1I1.14","DOIUrl":null,"url":null,"abstract":"Background:\n Molecular identification of mutations resulting in\n multidrug-resistant tuberculosis (MDR-TB) is an important approach for\n improving understanding of MDR-TB epidemiology and planning for\n appropriate interventions. We aimed to estimate the prevalence and\n distribution of mutations causing MDR-TB as well as determine the gene\n distribution among patients previously treated for TB. Methods: This was a\n cross-sectional, hospital-based study conducted from April 2017 to\n October 2018 at Kibong’oto Infectious Diseases Hospital (KIDH). KIDH is\n the national MDR-TB referral hospital. Participants were patients\n presumptively diagnosed with MDR-TB and referred to KIDH from district\n and regional hospitals across Tanzania. Sputum samples were collected\n and analysed using the Xpert MTB/RIF assay, direct sputum smear\n fluorescence microscopy, culture on Lowenstein-Jensen medium, and line\n probe assay using the GenoType MTBDRplus VER 2.0 system. Demographic\n information and mutation frequencies were reported as counts and\n percentages and analysed using descriptive statistics. Results: A total of 208\n (69.3%) participants had rpoB gene mutations\n conferring resistance to only rifampicin; 92 (30.7%) had\n rpoB, katG, and inhA\n mutations conferring resistance to rifampicin and isoniazid;\n 78 (26%) had rpoB and katG\n mutations conferring resistance to rifampicin and isoniazid;\n and 14 (4.7%) had rpoB and inhA\n mutations conferring resistance to rifampicin and\n isoniazid. Conclusion:\n The mutation prevalences identified in this study\n indicate the most frequent mutations were the S531L mutation of the\n rpoB gene, the S315T1 mutation of the\n katG gene, and the S315T mutation in the promoter\n region of the inhA gene. To control the emergence\n and spread of MDR-TB, drug sensitivity testing must be carried for\n GeneXpert-confirmed TB patients prior to initiating second-line anti-TB\n regimens.","PeriodicalId":11398,"journal":{"name":"East Africa Science","volume":"79 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prevalence and Distribution of Multidrug-Resistant\\n Mutations in Mycobacterium tuberculosis in Tanzania\",\"authors\":\"J. Mgogwe, H. Semvua, Oliva Safari, G. Kapanda, B. Nyombi, J. Chilongola\",\"doi\":\"10.24248/EASCI.V1I1.14\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background:\\n Molecular identification of mutations resulting in\\n multidrug-resistant tuberculosis (MDR-TB) is an important approach for\\n improving understanding of MDR-TB epidemiology and planning for\\n appropriate interventions. We aimed to estimate the prevalence and\\n distribution of mutations causing MDR-TB as well as determine the gene\\n distribution among patients previously treated for TB. Methods: This was a\\n cross-sectional, hospital-based study conducted from April 2017 to\\n October 2018 at Kibong’oto Infectious Diseases Hospital (KIDH). KIDH is\\n the national MDR-TB referral hospital. Participants were patients\\n presumptively diagnosed with MDR-TB and referred to KIDH from district\\n and regional hospitals across Tanzania. Sputum samples were collected\\n and analysed using the Xpert MTB/RIF assay, direct sputum smear\\n fluorescence microscopy, culture on Lowenstein-Jensen medium, and line\\n probe assay using the GenoType MTBDRplus VER 2.0 system. Demographic\\n information and mutation frequencies were reported as counts and\\n percentages and analysed using descriptive statistics. Results: A total of 208\\n (69.3%) participants had rpoB gene mutations\\n conferring resistance to only rifampicin; 92 (30.7%) had\\n rpoB, katG, and inhA\\n mutations conferring resistance to rifampicin and isoniazid;\\n 78 (26%) had rpoB and katG\\n mutations conferring resistance to rifampicin and isoniazid;\\n and 14 (4.7%) had rpoB and inhA\\n mutations conferring resistance to rifampicin and\\n isoniazid. Conclusion:\\n The mutation prevalences identified in this study\\n indicate the most frequent mutations were the S531L mutation of the\\n rpoB gene, the S315T1 mutation of the\\n katG gene, and the S315T mutation in the promoter\\n region of the inhA gene. To control the emergence\\n and spread of MDR-TB, drug sensitivity testing must be carried for\\n GeneXpert-confirmed TB patients prior to initiating second-line anti-TB\\n regimens.\",\"PeriodicalId\":11398,\"journal\":{\"name\":\"East Africa Science\",\"volume\":\"79 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-03-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"East Africa Science\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.24248/EASCI.V1I1.14\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"East Africa Science","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24248/EASCI.V1I1.14","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
背景:分子鉴定导致耐多药结核病(MDR-TB)的突变是提高对耐多药结核病流行病学认识和制定适当干预措施的重要方法。我们的目的是估计引起耐多药结核病的突变的流行和分布,并确定以前接受过结核病治疗的患者的基因分布。方法:这是一项以医院为基础的横断面研究,于2017年4月至2018年10月在Kibong 'oto传染病医院(KIDH)进行。KIDH是国家耐多药结核病转诊医院。参与者是推定诊断为耐多药结核病的患者,并从坦桑尼亚各地的区和区域医院转介到KIDH。使用Xpert MTB/RIF检测、直接痰涂片荧光显微镜、Lowenstein-Jensen培养基培养和基因型MTBDRplus VER 2.0系统的线探针检测收集和分析痰样本。人口统计信息和突变频率以计数和百分比报告,并使用描述性统计进行分析。结果:共有208名(69.3%)参与者携带rpoB基因突变,仅对利福平耐药;92例(30.7%)有rpoB、katG和inhA突变,导致对利福平和异烟肼耐药;78例(26%)有rpoB和katG突变,对利福平和异烟肼耐药;14例(4.7%)有rpoB和inhA突变,对利福平和异烟肼耐药。结论:本研究鉴定的突变流行率表明,最常见的突变是rpoB基因的S531L突变、katG基因的S315T1突变和inhA基因启动子区的S315T突变。为了控制耐多药结核病的出现和传播,在开始二线抗结核治疗方案之前,必须对genexpert确认的结核病患者进行药敏试验。
Prevalence and Distribution of Multidrug-Resistant
Mutations in Mycobacterium tuberculosis in Tanzania
Background:
Molecular identification of mutations resulting in
multidrug-resistant tuberculosis (MDR-TB) is an important approach for
improving understanding of MDR-TB epidemiology and planning for
appropriate interventions. We aimed to estimate the prevalence and
distribution of mutations causing MDR-TB as well as determine the gene
distribution among patients previously treated for TB. Methods: This was a
cross-sectional, hospital-based study conducted from April 2017 to
October 2018 at Kibong’oto Infectious Diseases Hospital (KIDH). KIDH is
the national MDR-TB referral hospital. Participants were patients
presumptively diagnosed with MDR-TB and referred to KIDH from district
and regional hospitals across Tanzania. Sputum samples were collected
and analysed using the Xpert MTB/RIF assay, direct sputum smear
fluorescence microscopy, culture on Lowenstein-Jensen medium, and line
probe assay using the GenoType MTBDRplus VER 2.0 system. Demographic
information and mutation frequencies were reported as counts and
percentages and analysed using descriptive statistics. Results: A total of 208
(69.3%) participants had rpoB gene mutations
conferring resistance to only rifampicin; 92 (30.7%) had
rpoB, katG, and inhA
mutations conferring resistance to rifampicin and isoniazid;
78 (26%) had rpoB and katG
mutations conferring resistance to rifampicin and isoniazid;
and 14 (4.7%) had rpoB and inhA
mutations conferring resistance to rifampicin and
isoniazid. Conclusion:
The mutation prevalences identified in this study
indicate the most frequent mutations were the S531L mutation of the
rpoB gene, the S315T1 mutation of the
katG gene, and the S315T mutation in the promoter
region of the inhA gene. To control the emergence
and spread of MDR-TB, drug sensitivity testing must be carried for
GeneXpert-confirmed TB patients prior to initiating second-line anti-TB
regimens.